Former AstraZeneca senior staff charged with illegal trade in Chinanews2026-02-11T20:24:40+00:00February 11th, 2026|Endpoints News|
Madrigal pads MASH pipeline with six siRNAs from China’s Ribonews2026-02-11T15:49:41+00:00February 11th, 2026|Endpoints News|
Sanofi invests in China startup GluBio in developing molecular glue for sickle cellnews2026-02-11T12:00:02+00:00February 11th, 2026|Endpoints News|
Shanghai’s Cascade gets $72M to pursue MASH, obesity and diabetes drugsnews2026-02-10T15:50:13+00:00February 10th, 2026|Endpoints News|
Hengrui, Kailera push obesity pill ahead on promising mid-stage China datanews2026-02-10T12:00:31+00:00February 10th, 2026|Endpoints News|
Lilly returns to Innovent to partner on cancer and immune diseasesnews2026-02-09T09:28:38+00:00February 9th, 2026|Endpoints News|
Angitia gets $130M Series D for pipeline of musculoskeletal drugsnews2026-02-05T12:30:10+00:00February 5th, 2026|Endpoints News|
China startup AccurEdit raises $75M for gene editing therapiesnews2026-02-03T16:13:27+00:00February 3rd, 2026|Endpoints News|
SanegeneBio licenses RNAi candidate to Genentech for $200M upfrontnews2026-02-02T14:35:38+00:00February 2nd, 2026|Endpoints News|
AstraZeneca pays $1.2B for CSPC’s long-acting obesity drugsnews2026-01-30T10:36:16+00:00January 30th, 2026|Endpoints News|
